MARTIN J TYLER 4
4 · DYNAVAX TECHNOLOGIES CORP · Filed Mar 12, 2012
Insider Transaction Report
Form 4
MARTIN J TYLER
VP Clinical Development & CMO
Transactions
- Award
Common shares
2012-03-08$0.58/sh+75,000$43,500→ 75,000 total - Exercise/Conversion
Option (Right to Buy)
2012-02-13−75,000→ 75,000 totalExercise: $0.58From: 2011-02-27Exp: 2019-02-26→ Common Stock (75,000 underlying) - Award
Restricted Stock Units
2012-03-09−150,000→ 150,000 totalExercise: $4.22Exp: 2022-03-08→ Common Stock (150,000 underlying)
Footnotes (3)
- [F1]Not applicable.
- [F2]On March 8, 2012, Dr. Martin exercised certain of his outstanding options for cash. No shares were sold in the market in connection with this exercise.
- [F3]These restricted stock units shall vest upon achievement of certain performance conditions, as described in the Current Report on Form 8-K, filed with the Securities and Exchange Commission on March 12, 2012.